ArticleThe Journal of clinical investigation2025

Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.

Vera Tiedje et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.